On or around 12/11/2019 (Date of last review)
Filing Date: December 11, 2019
According to the Complaint, Foamix Pharmaceuticals Ltd is a specialty pharmaceutical company that focuses on therapeutic challenges in dermatology.
This action stems from a proposed transaction announced on November 11, 2019, pursuant to which Foamix Pharmaceuticals Ltd. will be acquired by Menlo Therapeutics Inc.
On November 10, 2019, Foamix’s Board of Directors caused the Company to enter into an agreement and plan of merger with Menlo. Pursuant to the terms of the Merger Agreement, Foamix’s stockholders will receive 0.5924 shares of Parent common stock and one contingent stock right for each share of Foamix common stock they own.
On December 4, 2019, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.
Company & Securities Information
Defendant: Foamix Pharmaceuticals Ltd.
Industry: Biotechnology & Drugs
Ticker Symbol: FOMX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Eric Sabatini, et al. v. Foamix Pharmaceuticals Ltd., et al.
COURT: D. Delaware
DOCKET #: 19-CV-02257
JUDGE: Hon. Leonard P. Stark
DATE FILED: 12/11/2019
CLASS PERIOD START: 11/11/2019
CLASS PERIOD END: 12/11/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Rigrodsky & Long, P.A. (Wilmington)
RM Law, P.C. (Berwyn)
First Identified Complaint (FIC) Filings:
Complaint for Violation of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available